3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Surgery
1
Stress, Psychological
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Seminoma
1
Sarcoma
1
Recurrence
1
Postoperative Complications
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Intermittent Fasting
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Interventions
Dexamethasone
116
daratumumab
68
Lenalidomide
67
Bortezomib
55
pomalidomide
45
carfilzomib
40
Cyclophosphamide
33
Calcium Dobesilate
32
Specimen Handling
30
Biopsy
28
Magnetic Resonance Spectroscopy
25
isatuximab
20
belantamab mafodotin
20
talquetamab
17
iberdomide
17
fludarabine
17
Melphalan
15
dexamethasone acetate
14
dexamethasone 21-phosphate
14
auricularum
14
fludarabine phosphate
11
selinexor
10
elotuzumab
10
tocilizumab
9
X-Rays
8
Nivolumab
8
trametinib
7
Sirolimus
7
Whole-Body Irradiation
6
Mycophenolic Acid
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Neoadjuvant Therapy
×
90 days
×
Clear all
NCT07149857
2026-06-05
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2
Recruiting
60 enrolled